Scholarlink

<p>Nanocellulose demonstrates remarkable application potential in the pharmaceutical field due to its unique physicochemical properties. However, the rapid and multidisciplinary development in this field urgently requires systematic analysis of technological topics to identify future research directions. Based on 1822 patents related to pharmaceutical nanocellulose (1982–2024) from the incoPat database, this study integrates topic evolution models and frontier identification algorithms to conduct a thematic analysis, supplemented by literature validation. The results indicate a clear evolutionary trend in technology, marked by a shift from basic material applications toward intelligent and precision systems. Meanwhile, the study identifies three major technological frontiers: hot technologies (e.g., composite dressings made of bacterial cellulose and chitosan that address pressing clinical needs), emerging technologies (e.g., 3D-printed aerogel bone scaffolds and gene therapy microcapsules representing innovative directions), and declining technologies (e.g., certain light-responsive drug carriers and multifunctional composites limited by inherent drawbacks). Literature validation further consolidates these findings, underscoring nanocellulose as an ideal candidate for pharmaceutical R&amp;D due to its excellent biocompatibility and customizability; nevertheless, its clinical translation still commonly faces core challenges, including manufacturing processes, targeted delivery efficiency, and immunogenicity control. Based on this, the study outlines a future direction with the central goal of bridging the “innovation-translation gap” and promoting a substantive leap from functional composite development toward precise intervention in life processes. Achieving this transition relies on two pillars: first, overcoming translational bottlenecks in standardization, safety, and targeted delivery at the application level; and second, enabling intelligent material design and integration of interdisciplinary approaches at the technological level. The findings from this study offer a strategic framework essential for guiding future research and accelerating the clinical translation of nanocellulose in the pharmaceutical field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanocellulose patents in the pharmaceutical field: evolutionary trends, frontier identification, and future directions

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Ying Wang,
  • Zhijing Zhang,
  • Kai Zhao,
  • Hongmei Yuan

摘要

Nanocellulose demonstrates remarkable application potential in the pharmaceutical field due to its unique physicochemical properties. However, the rapid and multidisciplinary development in this field urgently requires systematic analysis of technological topics to identify future research directions. Based on 1822 patents related to pharmaceutical nanocellulose (1982–2024) from the incoPat database, this study integrates topic evolution models and frontier identification algorithms to conduct a thematic analysis, supplemented by literature validation. The results indicate a clear evolutionary trend in technology, marked by a shift from basic material applications toward intelligent and precision systems. Meanwhile, the study identifies three major technological frontiers: hot technologies (e.g., composite dressings made of bacterial cellulose and chitosan that address pressing clinical needs), emerging technologies (e.g., 3D-printed aerogel bone scaffolds and gene therapy microcapsules representing innovative directions), and declining technologies (e.g., certain light-responsive drug carriers and multifunctional composites limited by inherent drawbacks). Literature validation further consolidates these findings, underscoring nanocellulose as an ideal candidate for pharmaceutical R&D due to its excellent biocompatibility and customizability; nevertheless, its clinical translation still commonly faces core challenges, including manufacturing processes, targeted delivery efficiency, and immunogenicity control. Based on this, the study outlines a future direction with the central goal of bridging the “innovation-translation gap” and promoting a substantive leap from functional composite development toward precise intervention in life processes. Achieving this transition relies on two pillars: first, overcoming translational bottlenecks in standardization, safety, and targeted delivery at the application level; and second, enabling intelligent material design and integration of interdisciplinary approaches at the technological level. The findings from this study offer a strategic framework essential for guiding future research and accelerating the clinical translation of nanocellulose in the pharmaceutical field.